Azura Ophthalmics Limited

Azura Ophthalmics Limited is rated 3 out of 5 in the category pharmaceuticals. Read and write reviews about Azura Ophthalmics Limited. Based in Tel Aviv, Israel, Azura Ophthalmics is a clinical-stage biotechnology company developing an innovative portfolio of medicines – in combination with a novel drug delivery platform – to advance treatments for Meibomian gland dysfunction (MGD), the underlying cause of many ocular surface diseases such as DED, Blepharitis, and Contact Lens Discomfort. The company’s initial focus is to develop medicines to treat Meibomian gland dysfunction (MGD) by targeting the root cause of the disease to restore the natural flow of Meibomian gland secretions. For more information, visit azuraophthalmics.com.